

# **Rhinosinusitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/R151C7724874EN.html>

Date: May 2024

Pages: 129

Price: US\$ 6,499.00 (Single User License)

ID: R151C7724874EN

## **Abstracts**

The 7 major rhinosinusitis markets reached a value of US\$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 3.0 Billion by 2034, exhibiting a growth rate (CAGR) of 4.64% during 2024-2034.

The rhinosinusitis market has been comprehensively analyzed in IMARC's new report titled "Rhinosinusitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Rhinosinusitis refers to a medical condition in which the paranasal sinuses and the mucous membranes around the nasal passages become infected and inflamed. The disease is characterized by obstruction and/or nasal congestion or a runny nose with discharge that may drain at the back or front of the nose. Depending on its duration, the illness is classified as acute or chronic rhinosinusitis. The common symptoms of this ailment include difficulty breathing, swelling and pain throughout the face, stuffiness, headache, itchy nose, fatigue, discolored or cloudy nasal discharge, decreased sense of smell, persistent cough, etc. Additionally, individuals suffering from rhinosinusitis may experience swelling around the eyes, pus, phlegm, fever, sore throat, etc. The diagnosis of this disease is based on a review of the patient's symptoms and a physical examination with a nasal endoscopy. The healthcare professional may also perform diagnostic procedures, such as a computed tomography (CT) scan that combines X-rays to provide a detailed 3-D image of the affected areas.

The increasing incidences of allergies and bacterial or viral infections, which can irritate the nasal passage, leading to blockages and fluid accumulation, are primarily driving the rhinosinusitis market. In addition to this, the rising prevalence of various risk factors, including a weakened immune system, smoking, structural abnormalities in the nasal

cavity, certain comorbid medical conditions, etc., is also bolstering the market growth. Furthermore, the widespread adoption of over-the-counter pain relievers, such as acetaminophen, ibuprofen, aspirin, etc., to help reduce pain and fever associated with the disease is acting as another significant growth-inducing factor. Additionally, several key players are making extensive investments in R&D activities to launch novel diagnostic tools for early diagnosis of rhinosinusitis and treatment monitoring in patients. This, in turn, is also creating a positive outlook for the market. Moreover, the inflating utilization of topical intranasal therapy, since it can reduce inflammation and correct mucociliary dysfunction, is further propelling the market growth. Besides this, the emerging popularity of allergy shots (immunotherapy), which limit the body's reaction to specific allergens and help treat the symptoms, is expected to drive the rhinosinusitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the rhinosinusitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for rhinosinusitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the rhinosinusitis market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the rhinosinusitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the rhinosinusitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current rhinosinusitis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

Market Insights

How has the rhinosinusitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the rhinosinusitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the rhinosinusitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of rhinosinusitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of rhinosinusitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of rhinosinusitis by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of rhinosinusitis by type across the seven major markets?

How many patients are diagnosed (2018-2034) with rhinosinusitis across the seven major markets?

What is the size of the rhinosinusitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of rhinosinusitis?

What will be the growth rate of patients across the seven major markets?

### Rhinosinusitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for rhinosinusitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the rhinosinusitis market?

What are the key regulatory events related to the rhinosinusitis market?

What is the structure of clinical trial landscape by status related to the rhinosinusitis market?

What is the structure of clinical trial landscape by phase related to the rhinosinusitis market?

What is the structure of clinical trial landscape by route of administration related to the rhinosinusitis market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 RHINOSINUSITIS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
- 4.5 Competitive Intelligence

### **5 RHINOSINUSITIS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 RHINOSINUSITIS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

## 7.2 Epidemiology Scenario - Top 7 Markets

- 7.2.1 Epidemiology Scenario (2018-2023)
- 7.2.2 Epidemiology Forecast (2024-2034?)
- 7.2.3 Epidemiology by Age (2018-2034)
- 7.2.4 Epidemiology by Gender (2018-2034)
- 7.2.5 Epidemiology by Type (2018-2034)
- 7.2.6 Diagnosed Cases (2018-2034)
- 7.2.7 Patient Pool/Treated Cases (2018-2034)

## 7.3 Epidemiology Scenario - United States

- 7.3.1 Epidemiology Scenario (2018-2023)
- 7.3.2 Epidemiology Forecast (2024-2034?)
- 7.3.3 Epidemiology by Age (2018-2034)
- 7.3.4 Epidemiology by Gender (2018-2034)
- 7.3.5 Epidemiology by Type (2018-2034)
- 7.3.6 Diagnosed Cases (2018-2034)
- 7.3.7 Patient Pool/Treated Cases (2018-2034)

## 7.4 Epidemiology Scenario - Germany

- 7.4.1 Epidemiology Scenario (2018-2023)
- 7.4.2 Epidemiology Forecast (2024-2034?)
- 7.4.3 Epidemiology by Age (2018-2034)
- 7.4.4 Epidemiology by Gender (2018-2034)
- 7.4.5 Epidemiology by Type (2018-2034)
- 7.4.6 Diagnosed Cases (2018-2034)
- 7.4.7 Patient Pool/Treated Cases (2018-2034)

## 7.5 Epidemiology Scenario - France

- 7.5.1 Epidemiology Scenario (2018-2023)
- 7.5.2 Epidemiology Forecast (2024-2034?)
- 7.5.3 Epidemiology by Age (2018-2034)
- 7.5.4 Epidemiology by Gender (2018-2034)
- 7.5.5 Epidemiology by Type (2018-2034)
- 7.5.6 Diagnosed Cases (2018-2034)
- 7.5.7 Patient Pool/Treated Cases (2018-2034)

## 7.6 Epidemiology Scenario - United Kingdom

- 7.6.1 Epidemiology Scenario (2018-2023)
- 7.6.2 Epidemiology Forecast (2024-2034?)
- 7.6.3 Epidemiology by Age (2018-2034)
- 7.6.4 Epidemiology by Gender (2018-2034)
- 7.6.5 Epidemiology by Type (2018-2034)
- 7.6.6 Diagnosed Cases (2018-2034)

#### 7.6.7 Patient Pool/Treated Cases (2018-2034)

### 7.7 Epidemiology Scenario - Italy

#### 7.7.1 Epidemiology Scenario (2018-2023)

#### 7.7.2 Epidemiology Forecast (2024-2034?)

#### 7.7.3 Epidemiology by Age (2018-2034)

#### 7.7.4 Epidemiology by Gender (2018-2034)

#### 7.7.5 Epidemiology by Type (2018-2034)

#### 7.7.6 Diagnosed Cases (2018-2034)

#### 7.7.7 Patient Pool/Treated Cases (2018-2034)

### 7.8 Epidemiology Scenario - Spain

#### 7.8.1 Epidemiology Scenario (2018-2023)

#### 7.8.2 Epidemiology Forecast (2024-2034?)

#### 7.8.3 Epidemiology by Age (2018-2034)

#### 7.8.4 Epidemiology by Gender (2018-2034)

#### 7.8.5 Epidemiology by Type (2018-2034)

#### 7.8.6 Diagnosed Cases (2018-2034)

#### 7.8.7 Patient Pool/Treated Cases (2018-2034)

### 7.9 Epidemiology Scenario - Japan

#### 7.9.1 Epidemiology Scenario (2018-2023)

#### 7.9.2 Epidemiology Forecast (2024-2034?)

#### 7.9.3 Epidemiology by Age (2018-2034)

#### 7.9.4 Epidemiology by Gender (2018-2034)

#### 7.9.5 Epidemiology by Type (2018-2034)

#### 7.9.6 Diagnosed Cases (2018-2034)

#### 7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 RHINOSINUSITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

### 8.1 Guidelines, Management and Treatment

### 8.2 Treatment Algorithm

## **9 RHINOSINUSITIS - UNMET NEEDS**

## **10 RHINOSINUSITIS - KEY ENDPOINTS OF TREATMENT**

## **11 RHINOSINUSITIS - MARKETED PRODUCTS**

### 11.1 List of Rhinosinusitis Marketed Drugs Across the Top 7 Markets

#### 11.1.1 Dupixent (Dupilumab) - Regeneron/Sanofi

##### 11.1.1.1 Drug Overview

##### 11.1.1.2 Mechanism of Action

##### 11.1.1.3 Regulatory Status

##### 11.1.1.4 Clinical Trial Results

##### 11.1.1.5 Sales Across Major Markets

#### 11.1.2 Nucala (Mepolizumab) - GlaxoSmithKline

##### 11.1.2.1 Drug Overview

##### 11.1.2.2 Mechanism of Action

##### 11.1.2.3 Regulatory Status

##### 11.1.2.4 Clinical Trial Results

##### 11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## 12 RHINOSINUSITIS - PIPELINE DRUGS

### 12.1 List of Rhinosinusitis Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Tezepelumab - Amgen/AstraZeneca

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 Rimegepant - Pfizer

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

#### 12.1.3 CM 326 - KeyMed Biosciences

##### 12.1.3.1 Drug Overview

##### 12.1.3.2 Mechanism of Action

##### 12.1.3.3 Clinical Trial Results

##### 12.1.3.4 Safety and Efficacy

##### 12.1.3.5 Regulatory Status

#### 12.1.4 LYR-210 - Lyra Therapeutics

##### 12.1.4.1 Drug Overview

##### 12.1.4.2 Mechanism of Action

#### 12.1.4.3 Clinical Trial Results

#### 12.1.4.4 Safety and Efficacy

#### 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

### **13. RHINOSINUSITIS - ATTRIBUTE ANALYSIS OF KEY MARKETING AND PIPELINE DRUGS**

### **14. RHINOSINUSITIS – CLINICAL TRIAL LANDSCAPE**

#### 14.1 Drugs by Status

#### 14.2 Drugs by Phase

#### 14.3 Drugs by Route of Administration

#### 14.4 Key Regulatory Events

### **15 RHINOSINUSITIS - MARKET SCENARIO**

#### 15.1 Market Scenario - Key Insights

#### 15.2 Market Scenario - Top 7 Markets

##### 15.2.1 Rhinosinusitis - Market Size

###### 15.2.1.1 Market Size (2018-2023)

###### 15.2.1.2 Market Forecast (2024-2034?)

##### 15.2.2 Rhinosinusitis - Market Size by Therapies

###### 15.2.2.1 Market Size by Therapies (2018-2023)

###### 15.2.2.2 Market Forecast by Therapies (2024-2034?)

#### 15.3 Market Scenario - United States

##### 15.3.1 Rhinosinusitis - Market Size

###### 15.3.1.1 Market Size (2018-2023)

###### 15.3.1.2 Market Forecast (2024-2034?)

##### 15.3.2 Rhinosinusitis - Market Size by Therapies

###### 15.3.2.1 Market Size by Therapies (2018-2023)

###### 15.3.2.2 Market Forecast by Therapies (2024-2034?)

##### 15.3.3 Rhinosinusitis - Access and Reimbursement Overview

#### 15.4 Market Scenario - Germany

##### 15.4.1 Rhinosinusitis - Market Size

###### 15.4.1.1 Market Size (2018-2023)

###### 15.4.1.2 Market Forecast (2024-2034?)

##### 15.4.2 Rhinosinusitis - Market Size by Therapies

- 15.4.2.1 Market Size by Therapies (2018-2023)
- 15.4.2.2 Market Forecast by Therapies (2024-2034?)
- 15.4.3 Rhinosinusitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Rhinosinusitis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034?)
  - 15.5.2 Rhinosinusitis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.5.3 Rhinosinusitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Rhinosinusitis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034?)
  - 15.6.2 Rhinosinusitis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.6.3 Rhinosinusitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Rhinosinusitis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034?)
  - 15.7.2 Rhinosinusitis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.7.3 Rhinosinusitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Rhinosinusitis - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034?)
  - 15.8.2 Rhinosinusitis - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.8.3 Rhinosinusitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Rhinosinusitis - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034?)

#### 15.9.2 Rhinosinusitis - Market Size by Therapies

##### 15.9.2.1 Market Size by Therapies (2018-2023)

##### 15.9.2.2 Market Forecast by Therapies (2024-2034?)

#### 15.9.3 Rhinosinusitis - Access and Reimbursement Overview

### **16 RHINOSINUSITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

### **17 RHINOSINUSITIS MARKET - SWOT ANALYSIS**

#### 17.1 Strengths

#### 17.2 Weaknesses

#### 17.3 Opportunities

#### 17.4 Threats

### **18 RHINOSINUSITIS MARKET – STRATEGIC RECOMMENDATIONS**

### **19 APPENDIX**

## I would like to order

Product name: Rhinosinusitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/R151C7724874EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R151C7724874EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

